Nipocalimab plus certolizumab did not improve primary outcomes in active rheumatoid arthritis in the phase 2a DAISY-RA Study
Rituximab demonstrates significant real-world effectiveness and acceptable safety in Sjögren’s disease: Evidence from the PORTRESS registry
Anifrolumab demonstrates rapid and sustained disease control in real-world systemic lupus erythematosus study
RA flares assessed by FLARE-RA questionnaire linked to disease activity measures but not structural damage progression
Tight-control strategy with golimumab achieves high remission rates in early axial spondyloarthritis regardless of gut inflammation
Radiographic non-progression linked to greater low disease activity achievement in psoriatic arthritis patients on secukinumab
Dual-targeting chimeric antigen receptor T-cell therapy achieves prolonged remission in refractory systemic lupus erythematosus
